Blarcamesine, also known as Anavex 2-73, previously secured orphan drug designation from the FDA, a status intended to incentivize the development of treatments for rare diseases. The company now holds active investigational new drug applications across three primary therapeutic areas: Alzheimer’s disease, Rett syndrome, and Fragile X syndrome.
In section Market Quotes
Anavex Secures FDA Green Light for Fragile X Syndrome Trial
The Food and Drug Administration has cleared Anavex Life Sciences to launch clinical trials for blarcamesine, a therapeutic candidate targeting Fragile X syndrome. This regulatory approval allows the company to transition its investigational new drug application into the active testing phase for the rare genetic condition.
Interim CEO Terrie Kellmeyer described the clearance as a significant milestone, noting that the company intends to maintain its current momentum in clinical development. The study marks a shift in the biotech firm’s efforts to address the neurological manifestations associated with the syndrome, as leadership continues its collaborative approach with federal regulators to advance their broader pipeline.
Comments (0)
No comments yet. Be the first!